Platinum-Refractory Fallopian Tube Carcinoma
5 clinical trials · Condition
◉ Watch Platinum-Refractory Fallopian Tube Carcinoma
| Record | Firm | Date |
|---|---|---|
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589) | National Cancer Institute (NCI) | 2022-06-30 |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (NCT05271318) | TILT Biotherapeutics Ltd. | 2022-05-17 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
Track Platinum-Refractory Fallopian Tube Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.